Вортиоксетин

Denmark's Lundbeck today announced positive trial results with the experimental antidepressant Brintellix (vortioxetine) in adults with major depression (MDD) who changed antidepressant treatment after an inadequate response to a selective serotonin reuptake inhibitor (SSRI) or serotonin and noradrenaline reuptake inhibitor (SNRI).

The double-blind randomized REVIVE study compared the efficacy and tolerability of flexible dose treatment with Brintellix (10-20mg/day) versus agomelatine (25-50 mg/day) in nearly 500 patients with resistant MDD.

 Experimental Antidepressant Vortioxetine Shows Positive Results